Comorbidities, concomitant medications and potential drug‐drug interactions with interferon‐free direct‐acting antiviral agents in hepatitis C patients in Taiwan
Chen‐Hua Liu(National Taiwan University Hospital), Jia‐Horng Kao(National Taiwan University Hospital), Chih‐Lin Lin(Chung Shan Medical University Hospital), Jyh‐Jou Chen(Tainan University of Technology), Cheng‐Yuan Peng(China Medical University), Wei‐Wen Su(Taichung Veterans General Hospital), Yi‐Hsiang Huang(First Hospital of Lanzhou University), Ming‐Lung Yu(National Sun Yat-sen University), Pin‐Nan Cheng(National Cheng Kung University Hospital), C. Brooks-Rooney, Gin‐Ho Lo(E-Da Hospital), Chi‐Yi Chen(National Taiwan University), Qian Ma, Tsai‐Yuan Hsieh(Tri-Service General Hospital)
Cited by 52
Related Papers
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
|JNCI Journal of the National Cancer Institute|2005|569
Elbasvir–Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy
|Annals of Internal Medicine|2016|364